No Data
No Data
H.C. Wainwright Maintains OKYO Pharma(OKYO.US) With Buy Rating, Maintains Target Price $7
Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential
OKYO Pharma Says OK-101 Gains USAN Reflecting Role in Ocular Disease Modulation | NASDAQ:OKYO
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
Express News | HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target
OKYO Pharma Analyst Ratings